CytomX Therapeutics

Yahoo Finance • 10 days ago

Recurrent Head and Neck Cancer Squamous Cell Carcinoma Markets and Competition Outlook 2026-2030: Personalized Medicine Drives Revenue Growth, Reaching $4.61 Billion by 2030

Dublin, March 30, 2026 (GLOBE NEWSWIRE) -- The "Recurrent Head and Neck Cancer Squamous Cell Carcinoma Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report offers comprehensive insights on market size, reg... Full story

Yahoo Finance • 23 days ago

CytomX Unveils $250 Mln Offering Of Shares And Warrants To Advance Varseta-M And Other Pipeline

(RTTNews) - CytomX Therapeutics, Inc. (CTMX), a clinical-stage, oncology-focused biopharmaceutical company, announced that it has commenced an underwritten public offering of $250.0 million of shares and pre-funded warrants. CytomX expect... Full story

Yahoo Finance • 24 days ago

Stock Market Today, March 16: CytomX Therapeutics Surges After Positive Phase 1 Colorectal Cancer Data

CytomX Therapeutics(NASDAQ:CTMX), a biotech company that develops conditionally activated biologics for cancer treatment, closed Monday at $6.75, up 44.23%. The stock is jumping after releasing Phase 1 Varseta-M data in metastatic colorect... Full story

Yahoo Finance • 24 days ago

Sector Update: Health Care Stocks Advance Late Afternoon

Health care stocks rose late Monday afternoon, with the NYSE Health Care Index up 0.8% and the State PREMIUM Upgrade to read this MT Newswires article and get so much more. A Silver or Gold subscription plan is required to access premiu... Full story

Yahoo Finance • 24 days ago

J.P. Morgan outlines CRM options play for uncertain Iran war outcome

[Salesforce To Purchase Popular Messaging Platform Slack For 27 Billion] Stephen Lam/Getty Images News J.P. Morgan’s equity derivatives team, led by strategist Bram Kaplan, favors selling puts as a target-buy strategy on oversold, high-qu... Full story

Yahoo Finance • 24 days ago

BC-Most Active Stocks

NEW YORK (AP) — prices for the Nasdaq composite, NYSE and NYSE American listed most active stocks. Nasdaq most active stocks: Stock Name Volume High Low Last Change HCW Biologics Inc. 179,323,336 1.10 0.6775 1.03 +0.5139 Cytomx Therapeut... Full story

Yahoo Finance • 25 days ago

Quant snapshot: Micron, Babcock & Wilcox lead strong buys as Fold Holdings, Alvotech lag

Information technology, industrials and utilities are set to feature prominently in this week’s earnings calendar, with 249 companies scheduled to report. This week’s quant rankings highlight strong momentum among technology and industria... Full story

Yahoo Finance • 28 days ago

How The CytomX Therapeutics (CTMX) Story Is Shifting With Lofty P/E Assumptions And New Targets

Find your next quality investment with Simply Wall St's easy and powerful screener, trusted by over 7 million individual investors worldwide. CytomX Therapeutics is back in focus after recent Street research clustered around higher price... Full story

Yahoo Finance • 2 months ago

Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating

CytomX Therapeutics, Inc. (NASDAQ:CTMX) is among the 15 Best Small Cap Stocks to Buy According to Wall Street.Barclays Raises its Price Target on CytomX Therapeutics, Inc. (CTMX) to $10 and Maintains an Overweight Rating On February 4, 20... Full story

Yahoo Finance • 2 months ago

Analysts Bullish Ahead of Colorectal Cancer Readout for CytomX Therapeutics, Inc. (CTMX)

We recently compiled a list of the 20 Best Biotech Stocks Under $20 to Buy Now. The eighth stock on our list of best biotech stocks under $20 is CytomX Therapeutics, Inc. TheFly reported on January 20 that Piper Sandler raised its price t... Full story

Yahoo Finance • 4 months ago

CytomX Therapeutics to Present at Upcoming December Investor Conferences

SOUTH SAN FRANCISCO, Calif., Nov. 25, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that management will participate in the followin... Full story

Yahoo Finance • 5 months ago

CytomX Therapeutics to Present at the Jefferies London Healthcare Conference

SOUTH SAN FRANCISCO, Calif., Nov. 13, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive off... Full story

Yahoo Finance • 5 months ago

CytomX outlines Q1 2026 CX-2051 data update and 100-patient enrollment milestone as Phase Ib study nears

Earnings Call Insights: CytomX Therapeutics (CTMX) Q3 2025 MANAGEMENT VIEW * CEO Sean McCarthy announced the appointment of Rachael Lester as Chief Business Officer, emphasizing her "broad strategic planning and business development ex... Full story

Yahoo Finance • 5 months ago

CytomX Therapeutics Announces Third Quarter 2025 Financial Results and Provides Business Update

- CX-2051 Phase 1 data update on track for Q1 2026 - - CX-2051 Phase 1b CRC combination study with bevacizumab to start in Q1 2026 - - Positive CX-801 Phase 1 monotherapy biomarker data at SITC 2025 supportive of ongoing Phase 1 combinat... Full story

Yahoo Finance • 5 months ago

CytomX Therapeutics to Report Third Quarter 2025 Financial Results on November 6, 2025

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that it will report third quarter financial resu... Full story

Yahoo Finance • 6 months ago

CytomX Therapeutics Appoints Rachael Lester as Chief Business Officer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced the appointment of Rachael Lester as Senior Vice... Full story

Yahoo Finance • 8 months ago

CytomX Therapeutics Announces Second Quarter 2025 Financial Results and Provides Business Update

- May 12, 2025 announcement of positive interim data from ongoing Phase 1 study of CX-2051 (EpCAM Antibody Drug Conjugate) in patients with advanced colorectal cancer (CRC) - - CX-2051 Phase 1 dose expansions on track for data update in Q... Full story

Yahoo Finance • 8 months ago

CytomX Therapeutics to Report Second Quarter 2025 Financial Results on August 7, 2025

SOUTH SAN FRANCISCO, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologic therapeutics, today announced that it will report second quarter f... Full story

Yahoo Finance • 9 months ago

Breaking Through: Systemic Genetic Medicines for Hard-to-Treat Cancers

NetworkNewsWire Editorial Coverage NEW YORK, July 9, 2025 /CNW/ -- Each year, approximately 20 million people are diagnosed with cancer, and nearly 10 million lives are lost to the disease worldwide, a toll that is projected to rise in th... Full story

Yahoo Finance • 10 months ago

CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

SOUTH SAN FRANCISCO, Calif., May 29, 2025 (GLOBE NEWSWIRE) -- CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of masked, conditionally activated biologics, today announced that Sean McCarthy, D.Phil., chief executive offi... Full story